GILD

#86
Gilead Sciences, Inc. - Common Stock
134.4 3 USD
-0.85%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
134.41
134.48
1年のレンジ
104.46
157.27
1日の変化
-0.85%
月次変化
+5.06%
6か月変化
+6.95%
1年の変化
+20.44%
以前の終値
135.5 8
Open
134.4 8
安値
134.4 1
High
134.4 8
ボリューム
640
チャート全体を表示 Full chart

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 166.9 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry 医薬品メーカー（一般）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
18.96
売上高対価格比率
5.88
1株当たり配当金
0.82
配当利回り（％）
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

ニュース